Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
DIG-MSK (demycarosyl-3D-β-D-digitoxosyl-mithramycin SK) is a recently isolated compound of the mithramycin family of antitumor antibiotics, which includes mithramycin A (MTA) and mithramycin SK (MSK). Here, we present evidence that the binding of DIG-MSK to DNA shares the general features of other mithramycins such as the preference for C/G-rich tracts, but there are some differences in the strength of binding and the DNA sequence preferentially recognized by DIG-MSK. We aimed at gaining further insights into the DIG-MSK mechanism of action by direct comparison with the effects of the parental MTA. Similar to MTA, MSK and DIG-MSK accumulated rapidly in A2780, IGROV1 and OVCAR3 human ovarian cancer cell lines, and DIG-MSK was a potent inhibitor of both basal and induced expression of an Sp1-driven luciferase vector. This inhibitory activity was confirmed for the endogenous Sp1 gene and a set of Sp-responsive genes, and compared to that of MTA and MSK. Furthermore, DIG-MSK was stronger than MTA as inhibitor of Sp3-driven transcription and endogenous Sp3 gene expression. Differences in the effects of MTA, MSK and DIG-MSK on gene expression may have a large influence on their biological activities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cbi.2014.05.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mithramycin and its analogs: Molecular features and antitumor action.
Pharmacol Ther
August 2024
Instituto de Diagnóstico Ambiental y Estudios del Agua, CSIC, E-08034 Barcelona, Spain. Electronic address:
The antitumor antibiotic mithramycin A (MTA) binds to G/C-rich DNA sequences in the presence of dications. MTA inhibits transcription regulated by the Sp1 transcription factor, often enhanced during tumor development. It shows antitumor activity, but its clinical use was discontinued due to toxic side effects.
View Article and Find Full Text PDFThe use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.
Eur J Nucl Med Mol Imaging
August 2023
Department of Radiology, Memorial Sloan Kettering Cancer Center, 415 East 68th Street, Z-2064, New York, NY, 10065, USA.
Article Synopsis
- The study introduces a new dosimetry method using biomarker-based analysis to determine effective radioactive iodine treatment levels for patients with metastatic differentiated thyroid cancer (mDTC), relying on single-timepoint imaging of tumor uptake through I PET.
- Researchers conducted quantitative PET scans on 208 mDTC lesions from 21 patients to measure individual lesion radiation doses and created a predictive model showing that a 48-hour SUV measurement is the best predictor for the radiation dose each lesion receives.
- The findings demonstrate significant variability in radiation doses among lesions, suggesting a median dose of 22,000 cGy, and highlight the practicality of using I-PET imaging to personalize treatment plans for mDTC patients based on specific metrics obtained from just a single
ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes.
Nat Commun
June 2021
Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
One of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1 and TNNI3 double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression.
View Article and Find Full Text PDFPleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042).
PLoS One
June 2016
Department of Functional Biology, IUOPA, Universidad de Oviedo, Oviedo, Spain.
Demycarosyl-3D-ß-D-digitoxosyl-mithramycin SK (DIG-MSK) is a recently isolated analogue of mithramycin A (MTA) that showed differences with MTA in the DNA binding strength and selectivity. These differences correlated with a better therapeutic index and less toxicity in animal studies. Herein, we show that DIG-MSK displays a potent anti-tumor activity against different types of cancer cell lines, ovarian tumor cells being particularly sensitive to this drug.
View Article and Find Full Text PDFThe activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription.
Chem Biol Interact
August 2014
Instituto de Biología Molecular de Barcelona, CSIC, Parc Cientíific de Barcelona, E-08028 Barcelona, Spain. Electronic address:
DIG-MSK (demycarosyl-3D-β-D-digitoxosyl-mithramycin SK) is a recently isolated compound of the mithramycin family of antitumor antibiotics, which includes mithramycin A (MTA) and mithramycin SK (MSK). Here, we present evidence that the binding of DIG-MSK to DNA shares the general features of other mithramycins such as the preference for C/G-rich tracts, but there are some differences in the strength of binding and the DNA sequence preferentially recognized by DIG-MSK. We aimed at gaining further insights into the DIG-MSK mechanism of action by direct comparison with the effects of the parental MTA.
View Article and Find Full Text PDF